https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44990 p < 0.001), anti-MPO positive vs anti-MPO negative (38.5% vs 13.6%, p  = 0.006) and anti-PR3 positive vs anti-PR3 negative patients (44.4% vs 13.4%, p  < 0.001). A higher prevalence of interstitial lung disease (ILD) was found in the ANCA positive (44.8% vs 21.8%, p  < 0.001) and the anti-PR3 positive groups (50.0% vs 23.4%, p  = 0.009). In multivariable analysis, ANCA-positive status remained associated with ILD after adjusting for anti-Scl-70 antibodies. Pulmonary embolism (PE) was more common in ANCA-positive patients (8.6% vs 3.0%, p  = 0.002) and anti-PR3-positive patients (16.7% vs 3.3%, p  = 0.022). ANCA-positive status remained associated with PE in a multivariable analysis adjusting for anti-phospholipid antibodies. Kaplan-Meier analysis revealed increased mortality in ANCA-positive patients (p  = 0.006). In Cox regression analysis, ANCA was associated with increased mortality, after adjusting for age and sex. Conclusions: ANCA is associated with increased prevalence of ILD and PE in SSc. ANCA should be tested in SSc, as it identifies individuals with worse prognosis who require close monitoring for adverse outcomes.]]> Wed 26 Oct 2022 09:28:52 AEDT ]]> Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternative scenario analyses https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42332 STANDARD). Owing to the limitations of TTE, the ASIG developed a new screening algorithm (ASIGPROPOSED) utilising a serum biomarker, NT-proBNP, in place of TTE, which has been shown to be equally accurate as the current algorithm. The aim of this study was to compare the cost of these two algorithms using different scenarios. The new algorithm resulted in significant yearly cost savings of between AU$42 913.35 and AU$84 570 in screening and diagnosis of an Australian cohort which, if extrapolated to the Australian population, would result in a yearly cost saving of between AU$367 066 and AU$725 564. There was no scenario in which the proposed algorithm did not result in a cost saving.]]> Mon 22 Aug 2022 13:42:56 AEST ]]> Occupational silica exposure in an Australian systemic sclerosis cohort https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41823 Fri 17 Nov 2023 11:35:16 AEDT ]]>